February 24, 2015
Theravance Biopharma Enrolls First Patient in Phase 3 Registrational Study of Telavancin in Staphylococcus Aureus Bacteremia
February 10, 2015
Theravance Biopharma Initiates Patient Registry Study for VIBATIV(R) (telavancin)
February 4, 2015
Theravance Biopharma to Present at the Leerink Global Healthcare Conference
Medicines that make a difference®
We apply our multivalency expertise to discover, develop and commercialize small molecule medicines for significant unmet medical needs.
We pursue a best-in-class strategy designed to discover superior medicines across multiple therapeutic areas.
In some instances, we partner our programs in order to accelerate timelines and better align resources.
Every day at Theravance Biopharma, we think it through, find a way, and get it done so that together with our partners we can bring patients much needed new medicines.
Theravance Biopharma discovers, develops and brings important medicines to patients by: